The Winning Combination: Avanir’s Nuedexta Finally Cleared For Emotional Incontinence

Once feared for potentially harmful cardiovascular effects, Avanir Pharmaceuticals Inc.’s Nuedexta has become the first drug to gain FDA approval for treatment of the involuntary emotional disorder “pseudobulbar affect,” with no black box warning.